PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT) today announced issuance of U.S. patent application 8,703,485 related to inactivation of rodent immunoglobulin genes and generation of human antibodies. The issuance came with a patent term extension of 1,228 days and will further strengthen the intellectual property of the company’s OmniAb™ suite of human therapeutic antibody platforms, including OmniRat®, OmniMouse® and OmniFlic™.
Help employers find you! Check out all the jobs and post your resume.
